Protara Therapeutics, Inc. (TARA) stock
TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$2.32−0.06 (-2.52%)
Close on Nov 17, 2026Market cap $137.10MP/E –Yield –
Protara Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Protara Therapeutics's ebitda for the twelve months ending Sep 30, 2017 was -$31.49M. For fiscal 2016 it was -$28.58M. The highest annual figure on record is -$7.10M in fiscal 2013.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | -$28.58M | – |
| FY2015 | Dec 31, 2015 | -$20.81M | – |
| FY2014 | Dec 31, 2014 | -$7.55M | – |
| FY2013 | Dec 31, 2013 | -$7.10M | – |
| FY2012 | Dec 31, 2012 | -$7.94M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2017 | Sep 30, 2017 | -$12.27M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.95M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.44M | – |
| Q4 FY2016 | Dec 31, 2016 | -$6.83M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.13M | – |
See a number that looks wrong?